Philip Vickers

Philip J.
Vickers currently serves as President, Chief Executive Officer & Director at Solu Therapeutics, Inc., Director at Northern Mosaic LP, and Director at Akebia Therapeutics, Inc. (starting 2026).
Former roles include President, Chief Executive Officer & Director at Northern Biologics, Inc. (2017–2020), President, Chief Executive Officer & Director at Faze Medicines, Inc. (2021–2022), President, Director & Chief Scientific Officer at Resolvyx Pharmaceuticals, Inc. (2009–2011), Independent Director at Revance Therapeutics, Inc. (2015–2023), Director at Neusentis Ltd., Independent Director at AVROBIO, Inc. (2019–2024), Global Head-Research & Development at Shire Plc (2013–2017), Principal at Boehringer Ingelheim Corp., VP & Head-Pfizer Research Technology Center at Pfizer (St. Louis), and Principal at Merck Research Laboratories Massachusetts LLC.
Education includes undergraduate studies at the University of Salford and a doctorate from the University of Toronto.